Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan Dual Therapy for H. pylori Eradication
NCT06004401Not yet recruiting
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Aug 2023
- Primary completion
- Aug 2025
- Modality
- Small Molecules
01
Overview
Randomised, open-label trial of vonoprazan in Helicobacter pylori infection (4 arms), sponsored by Shanghai Changzheng Hospital. Primary endpoint: The eradication rate of Helicobacter pylori at 2 years. Planned start Aug 2023; status: not yet recruiting.
02
Drugs
vonoprazan
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT06004401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06004401.